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Upper airway dryness is a frequent side-effect of nasal continuous positive airway pressure (nCPAP) therapy in 
obstructive sleep apnoea (OSA). In this situation, heated humidification is often used. Alternatively, oily nose drops 
are frequently applied to relieve dryness. The present study aimed to investigate the efficacy of a heated humidifier 
in comparison with oily nose drops. 
Twenty-four OSA patients complaining of serious nCPAP-related upper airway dryness were randomized to 6 
weeks of treatment either with heated humidification (HC loo@‘, Fischer & Paykel, Inc., Auckland, New Zealand) 
or oily nose drops (Colda-Stop @, Desitin, Inc., Germany). The patients completed questionnaires on the degree and 
frequency of upper airway dryness, compliance with nCPAP, intention to terminate nCPAP and comfort during the 
nCPAP therapy. 
All 12 patients treated with heated humidification improved in terms of the degree and frequency of upper airway 
dryness, and reported greater comfort when using the nCPAP device. All patients in the heated humidification group 
intending to terminate nCPAP therapy because of upper airway dryness persisted with nCPAP on addition of 
humidification. In contrast, only five out of 12 patients (42%) in the oily nose drops group reported their degree 
of upper airway dryness to be improved (P=O.O03), only three patients (25%) reported an improvement in the 
frequency of upper airway dryness (P<O.OOl), and only five patients (42%) reported greater comfort when using 
the nCPAP device with oily nose drops (P<O.OOl). In the group using oily nose drops none of the three patients who 
intended to terminate nCPAP therapy persisted with nCPAP. 
Heated humidification is highly effective and superior to oily nose drops in reducing the symptoms of upper 
airway dryness during nCPAP. 
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Introduction 
Obstructive sleep apnoea syndrome (OSA) occurs in about 
4% of middle-aged men and 2% of middle-aged women (1). 
Sullivan et al. introduced nasal continuous positive airway 
pressure (nCPAP) therapy in 1981 (2) and this therapy has 
since become the treatment of choice for OSA. Numerous 
studies have demonstrated the efficacy of nCPAP therapy in 
terms of reducing symptoms (e.g. daytime sleepiness), 
improving long-term survival, and preventing such sequelae 
of OSA as cardiovascular complications (3-6). However, 
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there is a high frequency of troublesome side-effects under 
nCPAP. 
Among the most frequently reported side-effects of 
nCPAP is dryness of the nose, mouth and throat, which 
is experienced by 30-66% of patients on nCPAP ($7-11). 
To deal with this problem, heated humidification of the 
inspired air is often added to nCPAP therapy (11). 
Although the therapeutic efficacy of heated humidification 
has been estimated to be high (5,1 l-13), it has not yet been 
investigated in a prospective, randomized study. Alterna- 
tively, oily nose drops, which are much cheaper, are 
employed for the same purpose, but their efficacy has not 
yet been studied. 
The main purpose of our investigation was to examine 
the therapeutic efficacy of heated humidification in com- 
parison with oily nose drops in terms of the reduction of 
nCPAP-related upper airway dryness. A further aim was to 
determine whether patient tolerance of nCPAP can be 
increased by either of these measures. 
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TABLE 1. Questionnaires 
Pre- and post-study questions 
1. How would you evaluate the dryness of nose/mouth/throat during the past 14 days? 
None (1) Mild (2) Moderate (3) 
2. How often did you discontinue nCPAP during the past 14 days? 
Never (1) 1 day (2) l-7 days (3) 
3. How often did you suffer from dry nose/mouth/throat during the past 14 days? 
Never (1) l-4 days (2) 5-10 days (3) 
4. Would you terminate nCPAP because of nose/mouth/throat dryness? 
Yes No 
Post-study questions 
Severe (4) 
8-14 days (4) 
11-14 days (4) 
5. How would you evaluate the effect of the study treatment on dryness? 
No improvement (1) Some improvement (2) Considerable improvement (3) 
6. Did you find nCPAP more acceptable using the study treatment? 
No (1) Yes, somewhat (2) Yes, definitely (3) 
7. Did you experience any side-effects of the study treatment? 
No If yes, please describe . . . 
Complete elimination (4) 
Yes, considerably (4) 
Materials and Methods 
PATIENTS 
Between November 1996 and March 1997 we recruited 24 
consecutive OSA patients (22 men, two women, mean 
age 57.58 f 9.78 years, body mass index (BMI) 
29.92 f 3.98 kg m - 2, complaining of serious upper airway 
dryness caused by nCPAP therapy. In all cases the diagno- 
sis of OSA and the manual titration of the nCPAP pressure 
had been made by full-night polysomnographies (CNS- 
SleepLab, Jaeger and Toennies Inc., Germany) performed 
in our sleep laboratory using standard methods, as recom- 
mended by the American Thoracic Society (ATS) (14,15) 
and the German Sleep Society (DGSM) (16). While on 
nCPAP therapy all patients underwent periodical follow-up 
in our outpatient department. Only patients with an 
apnoea-hypopnoea index of at least 10 h - ’ were admitted 
to the study. The patients included had been on nCPAP 
therapy for a mean period of 14.75 f 14% months (2-51 
months). The mean pressure used during home treat- 
ment was 7.21 f 2.19 mbar. All patients employed the 
nCPAP device Somnotron 2@ (Weinmann Inc., Hamburg, 
Germany). 
(12 patients) or to an oily nose drops group (12 patients). 
The patients in the humidification group were treated for 
6 weeks with nCPAP added heated humidification, while 
those in the other group were given oily nose drops instead. 
At the end of the 6-week period the patients were again 
asked to complete the same questionnaire and to answer 
additional questions aimed at determining the results of 
treatment and possible side-effects (Table 1). The study 
protocol was examined 
Ethics Committee of the 
Erlangen-Nuremberg. 
STUDY TREATMENT 
Excluded from the study were patients older than 75 
years, those with a central sleep apnoea syndrome, Cheyne- 
Stokes respiration, significant daytime nasal obstruction, 
severe upper airways infection (e.g. febrile sinusitis) or 
chronic obstructive lung disease, and patients who had 
already been treated with a humidifier or with oily nose 
drops. 
For humidification we employed the heated humidifier HC 
lOO@ (Fischer & Paykel, Inc., Auckland, New Zealand), 
which was attached to the tube of the nCPAP device in 
accordance with the manufacturer’s recommendations. The 
air was humidified by heating boiled tap-water on the 
hot-plate of the humidifier. The temperature of the hot- 
plate can be set in steps between 1 and 9. Throughout the 
study the temperature setting of the hot plate was fixed at 5 
for each patient. The patients were instructed to employ the 
humidifier whenever they used the nCPAP system. 
As oily nose drops we used Colda-Stopa (Desitin, Inc., 
Germany) containing alkyl fatty acid ester, peanut oil, 
orange oil, lemon oil, terpineol, isopropyl myristate, 
a-tocopherol acetate and retinol palmitate. We prescribed a 
dose of 3 drops to be applied three times a day in each 
nostril. 
STUDY DESIGN QUESTIONNAIRE 
All patients were asked to complete a questionnaire (see 
later) in our outpatient department to provide information 
about the degree and frequency of dryness, and discontinu- 
ation of nCPAP (Table 1). With the aid of a randomization 
list the patients were randomized to a humidification group 
All patients completed a questionnaire (Table 1) before and 
after the study period. When designing the questionnaire we 
made every effort to make it uncomplicated and easy for the 
patient to understand. To this end we created seven simple 
items in the form of analogue visual scales (questions l-3 
and approved by the local 
Friedrich-Alexander-University 
UPPER AIRWAY DRYNESS IN CPAP 23 
TABLE 2. Characteristics (mean & SD) of patients by treat- 
ment group 
Humidification Oily nose drops 
(n=12) (n= 12) 
Male/female 1111 11/l 
Age (years) 58.33 dz 9,77 56.83 * 10.15 n.s. 
BMI (kg m-‘) 28.50 x!z 1.78 31.33 f 5.05 ns. 
Pressure (mBar) 7.00 zt 2.49 7.42 & 1.93 n.s. 
AH1 37.58 i= 17.09 39.00 f 21.11 ns. 
Duration of CPAP 16.08 f 14.75 13.42 f 15.48 n.s. 
(months) 
AH1 = apnoea-hypopnoea index; duration of CPAP = 
months receiving CPAP prior to the study; n.s.=not 
significant. 
and 5-6), and two ‘yes’ or ‘no’ questions (questions 4 
and 7). 
When completing the pre- and post-study questionnaires 
the patients were unaware of the aim of the study and the 
rationale of the study therapy. 
STATISTICAL METHODS 
All figures are expressed as arithmetic means & SD. For 
the statistical analysis of questions l-3 the patients were 
classified as ‘improved’ or ‘unchanged/worse’ and the two 
study groups were compared using Fisher’s exact test. 
Group comparisons for the analysis of questions 5 and 6 
were performed using the Mann-Whitney U-test. Group 
comparisons of patient characteristics, age, BMI, CPAP 
pressure, apnoea-hypopnoea index and duration receiving 
CPAP before the study, were carried out using the Student’s 
t-test. The statistical calculations were performed with 
the aid of SPSS (Version 6.0.1, SAS Institute, Inc., Cary, 
NC, U.S.A.). For differences between groups a two-tailed 
P-value of less than 0.05 was considered significant. 
Results 
PATIENTS 
For all 24 participants, the study was carried out in 
accordance with the protocol. 
Patient characteristics are summarized in Table 2. There 
were no statistically significant differences between the two 
groups in terms of age, sex, BMI, apnoea-hypopnoea 
index, nCPAP pressure and duration of nCPAP treatment 
prior to the study. 
EFFICACY OF THE STUDY TREATMENT 
The answers to the questions 1-3 are shown in Figs l-3. 
Significantly more patients in the heated humidification 
Humidification Oily nose drops 
FIG. 1. Question 1: ‘How would you evaluate the dryness 
of nose/mouth/throat during the past 14 days?‘. End-of- 
study dryness in comparison with pre-study: n , improved; 
q , no change/worse. 
I 7 P = 0.005, 
‘I 
IL 
1 
Humidification 
i 
Oily nose drops 
FIG. 2. Question 2: ‘How often did you discontinue 
nCPAP during the past 14 days?‘. Change in the number 
of nCPAP discontinuations during the study: n , fewer; 
0, unchanged/more. 
group reported a decrease in the severity of upper airway 
dryness (100 XS. 42%, P=O.O03), in the number of nCPAP 
discontinuations (66 vs. 8%, P=O.OOS) and the number of 
days suffering from dryness (100% vs. 25%, PcO.001) than 
in the oily nose drops group. 
The responses to questions 5 and 6 are shown in Figs 4 
and 5. In comparison with the patients in the oily nose 
drops group, those in the heated humidification group 
indicated significantly better results in terms of upper 
airway dryness (P<O.OOl) and improvement in comfort 
when using nCPAP (P<O.OOl). 
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Humidification Oily nose drops 
FIG. 3. Question 3: ‘How often did you suffer from dry FIG. 5. Responses to question 6: ‘Did you find nCPAP 
nose/mouth/throat during the past 14 days?. Difference more acceptable for you using the study treatment?. 
between pre- and post-study number of days suffering i, Yes, considerably or yes, definitely; q , yes, somewhat; 
from upper airway dryness: n , fewer; 0, unchanged/more. 0, no. 
r 
12 
1-P c 0.001, 
Humidification Oily nose drops 
1 
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FIG. 4. Responses to question 5: ‘How would you 
evaluate the effect of the study treatment on dryness?. 
n , Considerable improvement or complete elimination; 
LZ, some improvement; q , no improvement. 
SIDE-EFFECTS 
None of the patients in either group reported any severe 
side-effects of the study treatment, but there was a low rate 
of mild adverse reactions (oily nose drops group 8%; heated 
humidification group 33%). One patient in the oily nose 
drops group reported experiencing an unpleasant taste of 
oranges after using the nose drops. In the heated humidifi- 
cation group, four patients reported that condensed water 
collected inside the tube between the nCPAP device and the 
nasal mask, and one of these patients noted that his face 
under the mask was wet in the morning. 
r 
12 L 
7 P < O.OOlI 
Humidification Oily nose drops 
TERMINATION OF NCPAP THERAPY 
Prior to the start of the study, four patients randomized to 
the heated humidification group (33%) and three patients 
randomized to the oily nose drops group (25%) indicated 
that they would terminate nCPAP therapy because of upper 
airway dryness. In the heated humidification group all four 
patients indicated that they would continue nCPAP with 
humidification after the study. In contrast, the treatment 
with oily nose drops had no influence on the decision by the 
three patients to terminate nCPAP use. 
Discussion 
In summary, heated humidification was highly superior to 
oily nose drops in terms of the reduction of the severity and 
frequency of upper airway dryness under nCPAP. All 
patients treated with heated humidification reported an 
improvement. These results are in accordance with the 
postulates of many authors (5,17). The reduction in the 
number of nCPAP discontinuations in the heated humidi- 
fication group was higher than that in the oily nose drops 
group. This illustrates the fact that side-effects under 
nCPAP may result in noncompliance, whilst the elimination 
of side-effects may improve compliance with nCPAP 
therapy. Our investigation also showed that symptoms of 
upper airway dryness in particular may lead to definitive 
termination of nCPAP therapy. All patients intending to 
terminate nCPAP because of upper airway dryness contin- 
ued to use it under heated humidification. In contrast, the 
use of oily nose drops had no such effect. 
Heated humidifiers are superior to cold pass-over 
humidifiers since hot air can carry a higher maximum 
absolute humidity than cold air (13). The cheaper, cold 
pass-over humidifiers might nevertheless suffice for clinical 
purposes. This point needs to be studied in further clinical 
trials. Currently, we regard heated humidification as 
standard therapy for upper airway dryness under nCPAP. 
The present study was therefore designed to establish the 
therapeutic efficacy of a heated humidifier. 
For use in the present study we chose the most widely 
used heated humidification device in Germany, the HC 
lOO@ (Fischer & Paykel, Inc., Auckland, New Zealand). 
Since the degree of moisturization obtained with other 
devices may differ from that of the HC lOOa, the results of 
this study may not apply unreservedly to other such 
devices. 
Oily nose drops are often used to treat symptoms of 
dryness in the nose, particular by specialists in oto- 
rhinolaryngology. A positive effect on the symptoms of 
nose dryness by oily nose drops has been described in 
patients with rhinitis sicca, ozena, drug-induced rhinopathy 
and during the postoperative period in patients undergoing 
surgery on the nose (18). This positive effect was explained 
by postulating the formation of a lipid layer on the nasal 
mucosa that protects it from drying out. No systemic effect 
of such nose drops has been described to date. This means 
that a positive effect on the symptoms of dryness in the 
nose, but not in the mouth or throat, may be expected with 
the nose drops used in our study. Negative effects of such 
drops, for example on the symptoms of upper airway 
dryness, have not so far been described and would seem 
extremely unlikely. 
For the patients, of course, the alternatives, heated 
humidification or oily nose drops, are quite different. Thus 
a blind study design could not be employed. 
Although we did not find any serious side-effects of 
heated humidification, the study does not rule out the 
possibility that significant side-effects may arise from the 
long-term use of heated humidification. One might expect, 
in particular, an increased incidence of infections of the 
airways, since the humidification chamber offers good 
conditions for colonization by micro-organisms. Bacterial 
and fungal colonization of similar devices, such as oxygen 
concentrators and inhalers, has repeatedly been demon- 
strated (19). This fact underlines the importance of proper 
and frequent cleaning of heated humidifiers. With regard to 
the HC lOOa humidifier, a microbiological study done in 13 
patients showed significant bacterial and fungal coloniz- 
ation of the humidification chamber and the mask (20) 
when boiled tap-water was used for humidification, as in 
our case. However, none of the 13 patients developed 
infection of the upper or lower respiratory system, which is 
in accordance with our own observation that no patient 
showed symptoms of upper or lower airway infection under 
heated humidification. 
The only adverse reaction from heated humidification 
reported by our patients during the study period was 
condensation of water within the tube and mask, result- 
ing from hot moist air cooling down within the tube. In 
our study the incidence of this adverse reaction was 
particularly high because no change in the hot-plate tem- 
perature was allowed. By decreasing the temperature of the 
hot plate, condensation could have been reduced or 
avoided. 
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Heated humidification has been shown to be an effective 
and safe treatment of the symptoms associated with 
nCPAP-related upper airway dryness in OSA patients, thus 
preventing termination of nCPAP therapy. Heated humidi- 
fication is superior to oily nose drops. We suggest heated 
humidification as standard treatment of upper airway 
dryness due to nCPAP. 
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